Navigation Links
Arthritis patients failing to take expensive medication, according to new research
Date:8/28/2014

Twenty seven per cent of rheumatoid arthritis patients in the study who were on a class of drugs known as anti-TNF therapies did not take them as prescribed in the first six months. Patients from Manchester Royal Infirmary were among those from 60 hospitals around the UK involved in the study.

Researchers from the Arthritis Research UK Centre for Genetics and Genomics at The University of Manchester, who led the study, warned that failure to take the drugs correctly, known as 'non-adherence', reduced their effectiveness and may lead to a worsening of patients' disease.

Their results are published today (August 28 2014) in the journal Rheumatology.

One of the study's authors, Dr Kimme Hyrich, reader in rheumatology at The University of Manchester and honorary consultant at Manchester Royal Infirmary added: "If patients do not take their medication as prescribed it is likely to have a significant effect on whether they respond to therapy and could mean that their condition deteriorates more quickly affecting their quality of life. Non-adherence is also a waste of scarce healthcare resources and something that needs to be addressed."

It is not clear from the study whether patient's non-adherence was deliberate or accidental, but for many patients with this chronic disease, it is expected that they will need to remain on these therapies for many years. Research is ongoing to try and understand more about the reasons why patients with arthritis may not always take their medications as prescribed.

Rheumatoid arthritis affects around 400,000 people in the UK and is caused by the body's immune system turning on itself, leading to inflammation pain and swelling in the joints and other internal organs.

The development by Arthritis Research-funded scientists of biologic drugs such as anti-TNF therapy, which block the tumour necrosis factor (TNF) pathway in the inflammatory process that causes rheumatoid arthritis has revolutionised treatment worldwide in the past 10-15 years, and transformed the lives of millions of patients. But it is expensive, costing between 8,000 and 12,000 a year per patient.

Professor Alan Silman, medical director of Arthritis Research UK, said: "Anti-TNF drugs have transformed the lives of a substantial number of patients with rheumatoid arthritis and related disorders. This success has been at a considerable cost to the NHS but there was always the assumption that patients prescribed these drugs will have the necessary regular injections. The fact that a considerable proportion of patients are missing doses of these very expensive agents is worrying, as clearly their effectiveness would be reduced."

Researchers collected adherence data for 286 patients attending 60 rheumatology clinics across the UK between 2008 and 2012 who had rheumatoid arthritis for seven years. Of these, 27 per cent reported non-adherence to biologic therapy according to the defined criteria at least once over the first six-month period.

Self-reported non-adherence, defined as whether a dose of anti-TNF therapy is taken on the day agreed with the health professional, was recorded at three and six months.

The study captured data from patients attending 60 different hospitals across the UK and was funded by Arthritis Research UK and the Manchester National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit.


'/>"/>

Contact: Ali Barbuti
alison.barbuti@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis
2. Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain
3. Sanofi-Aventis and Bioventus Products Globally Preferred to Treat Resilient Knee and Hip Pain for Sports Medicine and Osteoarthritis Applications
4. A new cause of osteoarthritis identified by research on a rare disease
5. Psoriatic arthritis patients need better screening, warns panel of experts
6. LCBO Stores Raise Funds for The Arthritis Society
7. Omega 3 fatty acids lessen severity of osteoarthritis in mice
8. Genotyping can predict disease outcomes in rheumatoid arthritis patients
9. Biomarkers predict long-term outcomes in juvenile idiopathic arthritis
10. Benaroya Research Institute scientists identify drivers of rheumatoid arthritis
11. One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... designed to appear more modern and approachable in their community. Delia Associates created ... to provide treatment for those dealing with substance abuse in the greater Hunterdon ...
(Date:12/13/2018)... YORK (PRWEB) , ... December 13, 2018 , ... Researchers ... of two classes of drugs that induces the highest rate of proliferation ever observed ... is an important step toward a diabetes treatment that restores the body’s ability to ...
(Date:12/13/2018)... ... ... Mediaplanet today announces the launch of this December’s issue of “Transplants: The Gift ... to sign up as an organ and/or whole-body donor for the 120,000 people in ... organ donor can save up to 8 lives, however, an average of 22 people ...
(Date:12/13/2018)... ... December 13, 2018 , ... Individuals who are interested ... to win a full-ride scholarship offered by Dr. Kami Hoss of Howard Healthcare Academy. ... The full-ride scholarship would enable a student to become a registered dental assistant for ...
(Date:12/10/2018)... ... 10, 2018 , ... Loma Linda University School of Public Health ... found a link with freight-railyard pollution to asthma-related emergency room visits in children. The ... large-scale railyard study is a follow-up to the i nitial study of ...
Breaking Medicine News(10 mins):
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... disease diagnostics with genomics, announced today the results of an ongoing clinical study ... showed that the Karius® Test, a non-invasive blood test that detects pathogen cell-free ...
(Date:12/10/2018)... (PRWEB) , ... December 10, 2018 , ... ... are pleased to announce the formation of Parkview Dental Partners (“Parkview Dental”), a ... Dr. Kenneth Liszewski, founder of BayView Dental, a group dental practice comprised of ...
(Date:12/8/2018)... (PRWEB) , ... December 07, 2018 , ... ... eye care practice management organizations in the nation, and Southwestern Eye Center, an ... Eye Center. The affiliation of the two businesses will improve the quality of ...
Breaking Medicine Technology: